Phaseline

Companies › Arvinas

Arvinas: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ARV-806
KRAS G12D degrader (targeted protein degradation)
KRASPhase 1KRAS G12D MutationNov 2026
ARV-393
Protein degrader (PROTAC)
–Phase 1Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Mar 2028
ARV-6723
Immune system activator for cancer cell recognition and destruction
–Phase 1Advanced Solid TumorMar 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07023731ARV-806Phase 1KRAS G12D MutationOncologyNov 2026
NCT06393738ARV-393Phase 1Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)OncologyMar 2028
NCT07749586ARV-6723Phase 1Advanced Solid TumorOncologyMar 2031

From the company's SEC filings

Cash and short-term investments of $558m on 2026-09-30; operating cash outflow about $172m a year; runway about 39 months at that burn, to Dec 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.